Skip to content
HowShorted

Zentalis Pharmaceuticals, Inc. short interest in 2023

In 2023, Zentalis Pharmaceuticals, Inc.'s disclosed short interest ran from 13.79% of shares outstanding on 13 Jan 2023 to 18.01% on 29 Dec 2023, a change of +4.22 percentage points. The year's high was 24.41% on 30 Jun 2023 and its low 13.16% on 31 Jan 2023, averaging 16.99% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 36.92 days on 14 Jul 2023. Full history: Zentalis Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Zentalis Pharmaceuticals, Inc. in 2023

2023 in figures

Start of year
13.79% (13 Jan 2023)
End of year
18.01% (29 Dec 2023)
Change
+4.22 pp
High
24.41% (30 Jun 2023)
Low
13.16% (31 Jan 2023)
Average
16.99%
Highest days to cover
36.92 (14 Jul 2023)
SEC filings marked
8

Every report in 2023

Zentalis Pharmaceuticals, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202313.79%9.70
31 Jan 202313.16%17.89
15 Feb 202313.86%14.77
28 Feb 202313.47%17.03
15 Mar 202313.59%17.6710-K filed, results (8-K)
31 Mar 202314.97%12.66
14 Apr 202315.16%17.27
28 Apr 202316.55%15.34
15 May 202317.88%11.9010-Q filed, results (8-K)
31 May 202320.70%8.24
15 Jun 202322.33%11.28
30 Jun 202324.41%12.49
14 Jul 202323.09%36.92
31 Jul 202322.42%32.55
15 Aug 202317.54%26.7310-Q filed, results (8-K)
31 Aug 202317.00%31.63
15 Sep 202316.00%15.78
29 Sep 202315.97%12.83
13 Oct 202315.16%12.39
31 Oct 202315.78%13.02
15 Nov 202314.95%4.5010-Q filed, results (8-K)
30 Nov 202315.68%21.09
15 Dec 202316.38%10.23
29 Dec 202318.01%14.14

See also: Zentalis Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.